ArticleCNS neuroscience & therapeutics2025
DeSUMOylation of IGF2BP2 Promotes Neuronal Differentiation of OM-MSCs by Stabilizing SOX11 to Ameliorate Brain Injury After Intracerebral Hemorrhage.
Article in CNS neuroscience & therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Olfactory Mucosa MSCs-Derived Exosomal RPL6 Attenuates Seizure-Induced Neuronal Damage via FGF2-Mediated Oxidative Stress and Mitophagy.Neurochemical research · 2026Article
- The role of stem cells and their engineering strategies in the repair of nerve damage in intracerebral hemorrhage.Cell & bioscience · 2026Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundOur previous study demonstrated that olfactory mucosa mesenchymal stem cell (OM-MSC) neuronal differentiation can reduce neural damage following intracerebral hemorrhage (ICH). However, the mechanisms that regulate OM-MSC neuronal differentiation to mitigate ICH-induced brain injury remain unclear.
methodsThe ICH model was established through autologous blood injection to evaluate the impact of OM-MSCs on brain injury, using the mNSS method, TUNEL, and Nissl staining, as well as the Western blot assay. qPCR, Western blotting, flow cytometry, and immunofluorescence assays were employed to assess the neuronal differentiation of OM-MSCs. The SUMOylation assay was conducted to investigate the relationship between IGF2BP2 and SENP1. RIP, RNA pull-down, and mRNA stability assays were performed to analyze the molecular interaction network involving SENP1, IGF2BP2, and SOX11.
resultsIGF2BP2 enhanced the protective effects of OM-MSCs against ICH-induced brain injury, as demonstrated by a significant reduction in brain edema, mNSS scores, and apoptosis, along with improved neuronal survival. Furthermore, the overexpression of IGF2BP2 increased the expression of Tuj-1, MAP2, NF200, and NeuN, while decreasing GFAP and ALDH1L1 levels, suggesting the stimulatory effects of IGF2BP2 on the neuronal differentiation of OM-MSCs. Mechanistically, SENP1 enhanced IGF2BP2 expression through SUMO1-induced IGF2BP2 SUMOylation. Additionally, IGF2BP2 functioned as an RNA-binding protein for SOX11, thereby increasing SOX11 levels. The depletion of IGF2BP2 negated the SENP1-induced neuronal differentiation of OM-MSCs. The overexpression of SOX11 mitigated the inhibitory effects of IGF2BP2 silencing on OM-MSC neuronal differentiation.
conclusionThe SENP1/IGF2BP2/SOX11 axis played a crucial role in the neuronal differentiation of OM-MSCs and ameliorated brain damage caused by ICH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.